These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 6265632)
1. The chemotherapy of protozoal infections: whither? Steck EA J Protozool; 1981 Feb; 28(1):30-5. PubMed ID: 6265632 [No Abstract] [Full Text] [Related]
2. Chemotherapy of leishmaniasis in India. Thakur CP Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933 [No Abstract] [Full Text] [Related]
3. Recent advances in the treatment of visceral leishmaniasis. Davidson RN; Croft SL Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221 [No Abstract] [Full Text] [Related]
5. Treatment of kala azar. Ozsoylu S Lancet; 1996 Jun; 347(9016):1701. PubMed ID: 8642997 [No Abstract] [Full Text] [Related]
6. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis. de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769 [No Abstract] [Full Text] [Related]
7. [Cutaneous leishmaniasis]. Vion B Rev Med Suisse Romande; 1989 Jun; 109(6):443-9. PubMed ID: 2547241 [No Abstract] [Full Text] [Related]
8. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation. Berhe N; Ali A; Hailu A; Yeneneh H Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358 [TBL] [Abstract][Full Text] [Related]
9. [Visceral leishmaniasis: new drugs]. Minodier P; Robert S; Retornaz K; Garnier JM Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780 [TBL] [Abstract][Full Text] [Related]
10. Glucantime-resistant visceral leishmaniasis in immunocompromised patients. Verdejo J; Alvar J; Polo RM; González-Lahoz JM Am J Med; 1988 Jul; 85(1):128. PubMed ID: 3389377 [No Abstract] [Full Text] [Related]
12. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds]. Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634 [No Abstract] [Full Text] [Related]
13. [Leishmaniasis caused by Leishmania viannia braziliensis (Lvb). A case of atypical course]. Costa JM; Vale KC; França F; Lago EL; Magalhães AV; Marsden PD; Sampaio RN Rev Soc Bras Med Trop; 1988; 21(2):71-3. PubMed ID: 2854901 [No Abstract] [Full Text] [Related]
14. [Treatment of visceral leishmaniasis in children]. Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279 [TBL] [Abstract][Full Text] [Related]
16. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety]. Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667 [TBL] [Abstract][Full Text] [Related]
17. Treatment of kala-azar in India. Thakur CP Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871 [No Abstract] [Full Text] [Related]
18. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis. Amusategui I; Sainz A; Tesouro MA Ann N Y Acad Sci; 1998 Jun; 849():447-9. PubMed ID: 9668510 [No Abstract] [Full Text] [Related]
19. Effects of antimonial therapy for canine leishmaniasis on antibody titer. Amusategui I; Sainz A; Tesouro MA Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509 [No Abstract] [Full Text] [Related]
20. Control of visceral leishmaniasis in Somalia: achievements in a challenging scenario, 2013–2015. Wkly Epidemiol Rec; 2017 Sep; 92(35):566-72. PubMed ID: 28945058 [No Abstract] [Full Text] [Related] [Next] [New Search]